Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02220803
Other study ID # CA-BP13
Secondary ID 2013-004866-33
Status Completed
Phase Phase 2
First received August 18, 2014
Last updated August 15, 2016
Start date March 2014
Est. completion date August 2016

Study information

Verified date August 2016
Source Göteborg University
Contact n/a
Is FDA regulated No
Health authority Sweden: Regional Ethical Review BoardSweden: Medical Products Agency
Study type Interventional

Clinical Trial Summary

This is a short term open, randomized cross over trial to explore and compare the efficacy of pharmacological carbonic anhydrase (CA) inhibition on obstructive sleep apnea (OSA) related hypertension. Patients will be randomized to receive Acetazolamide(Diamox®)(ACZ), Continuous Positive Airway Pressure (CPAP)or CPAP plus ACZ for 2 weeks. Following a 2 week wash-out period all study participants will receive the alternative treatment regimen. The total length of the study will be 10 weeks. The effects of carbonic anhydrase inhibition on blood pressure,hemodynamics and sleep apnea will be investigated.

Study hypothesis:

Carbonic anhydrase inhibition alone or in combination with nCPAP will prominently reduce blood pressure in patients with OSA. Further it is hypothesized that CA inhibition will induce a direct pharmacological effects on vascular stiffness as evidenced in overnight non-invasive assessments of vascular stiffness and that this effect will be particularly strong in patients also responding with a reduction of blood pressure.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date August 2016
Est. primary completion date August 2016
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Provision of informed consent prior to any study specific procedures

- Males 18 to 75 years

- An Apnea-Hypopnea Index (AHI)>15 and an Epworth Sleepiness Scale score (ESS)>6 as verified by a PSG recording.

- Patients with established hypertension (systolic/diastolic blood pressure >= 160/95, either systolic or diastolic accounted for).

- Clinically normal physical findings and laboratory values, as judged by the investigator

- Body mass index >= 35 kg/m2

Exclusion Criteria:

- Hypersensitivity to sulfonamides or acetazolamide-

- Patients with ongoing medication with other sulphonamides or patients any specific antihypertensive treatment.

- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity.

- Subjects with a seizure disorder

- Patients with clinically verified central sleep apnea

- Clinically significant renal (serum creatinine >2.0 mg/dL or >130 micromol/L), neurological, metabolic (e.g. Type 1 or 2 diabetes), haematological or hepatic disease (ASAT or ALAT >2 times the upper limit of normal).

- Subjects with an occupational risk potentially exaggerated by daytime sleepiness such as handling complex machinery or professional driving

- Unstable angina pectoris, unstable hypertension (or poorly controlled diabetes (HbA1C < 52 mmoles/mol, or fasting plasma glucose >7 mmoles/l).

- Clinically significant congestive heart failure.

- Myocardial infarction or coronary vessel intervention within the previous 6 months period.

- Subjects with uncontrolled hypertension (defined as a diastolic blood pressure =110 mmHg and/or a systolic blood pressure =180 mmHg with or without medication).

- Previously diagnosed or treated clinically significant cardiac arrhythmia

- Clinically significant chronic pulmonary or gastrointestinal disease.

- Clinical history of depression as judged by the investigator or other previous or present clinically significant psychiatric disease

- Suspected or confirmed poor compliance

- Alcohol or drug abuse during the last year.

- Subjects with any other significant condition that, in the opinion of the investigator, could interfere with participation in the study.

- Severe nocturnal hypoxia defined as more than 10 episodes with an oxygen desaturation exceeding 50% or signs of lacking resaturation between desaturations on previous recordings according to investigators judgment

- Participation in another clinical study during the last 6 months.

- Inability to understand and complete the questionnaires.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Acetazolamide
Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
Device:
nasal Continuous Positive Airway Pressure (nCPAP)


Locations

Country Name City State
Sweden Center for Sleep and Vigilance disorders Gothenburg Vastra Gotaland

Sponsors (1)

Lead Sponsor Collaborator
Göteborg University

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Other outcome measures include the assessment of vascular function. Vascular function will be assessed by:
Cold pressor test: assessing vascular response and pulse excitability. Arteriograph: Standard radial pulse assessment to determine pulse wave and augmentation.
Aritmethic stress test: Evaluate cardiovascular responses such as heart rate, blood pressure and heart rate variability induced by mental work.
CardioPAT: Finger plethysmograph measuring peripheral arterial tone as well as endothelial function following brachial artery compression (ischemia).
Full overnight two channel MC Cardio recorder (Sleep apnea indices and recording of continuous oximetry signal for vascular stiffness, microcirculation and chemosensory vascular responsiveness)
Markers of OSA include:
Baseline to 10 weeks Yes
Other Markers of OSA such as oxygen desaturation, mean overnight oxygenation, and sleep quality (by polygraphic (PG) assessment, daytime sleepiness, patient-reported outcomes as well as effects on metabolic markers. Markers of OSA include: Oxygen desaturation (ODI, events/hour), Mean overnight oxygenation (Spo2, %), Daytime sleepiness: Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire (FOSQ).
Patient reported outcomes include: Clinical Global rating Impression and Severity (CGI/S), Columbia suicidal severity rating scale (CSSR-S) Metabolic markers include:Total Cholesterol, HDL, LDL, Triglycerides, Insulin, HbA1C, Fasting plasma glucose and cathecholamines.
Baseline to 10 weeks No
Primary The primary efficacy variable is the reduction in systolic/diastolic office blood pressure (mmHg) between the treatment regimens The effect will be expressed in terms systolic and diastolic blood pressure (resting office, provoked office and 24 hour). Baseline to 10 weeks Yes
Secondary The secondary objective is to investigate the direct effect of CA inhibition on sleep disordered breathing (Apnea-hypopnea Index, AHI score (events/hour) in the subgroup of patients with OSA after treatment Secondary objectives include Apnea-hypopnea Index, AHI score in patients with OSA after treatment. Baseline to 10 weeks No
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A